When did Rigel Pharmaceuticals report Q4 2024 earnings?

Rigel Pharmaceuticals (RIGL) reported Q4 2024 earnings on March 4, 2025 after market close.

What were Rigel Pharmaceuticals's Q4 2024 revenue and EPS?

Rigel Pharmaceuticals reported revenue of $57.6M and eps of $0.80 for Q4 2024.

Did Rigel Pharmaceuticals beat estimates in Q4 2024?

Revenue beat the consensus estimate of $57.6M by $6.0K. EPS beat the consensus estimate of $0.30 by $0.50.

Where can I find Rigel Pharmaceuticals's Q4 2024 SEC filings?

You can read the 10-K periodic report (0001558370-25-002169) directly on SEC EDGAR. The filing index links above go to sec.gov.

Rigel Pharmaceuticals RIGL Q4 2024 Annual earnings

Reported March 4, 2025 · After market close

Revenue$57.6MIn line

EPS$0.80Beat by $0.50

Revenue estimate$57.6M

EPS estimate$0.30

Next report

Aug 4, 2026 (In 6 days)

Revenue estimate$55.3M

EPS estimate$0.13

Financials

Q4 2024

Income statement

See full

Revenue$57.6M+60.9%

Gross profit$51.8M+61.9%

Operating income$16.7M—

Net income$14.3M—

EPS (diluted)$0.81+225%

Balance sheet

See full

Cash & equivalents$56.7M+73.1%

Total debt$285.0K-70.8%

Total equity$3.3M+111%

Total assets$164.0M+39.9%

Cash flow

See full

Operating cash flow$14.5M+332%

Valuation & ratios

Valuation

as of 12/31/24

See full

Market cap$296.28M+17.2%

Enterprise value$239.82M+8.5%

P/E16.9×—

P/S1.7×-0.5×

Profitability

See full

Gross margin89.6%-4.3pp

Operating margin13.5%+8.5pp

Net margin9.8%+5.8pp

Returns & leverage

See full

Debt / equity0.1×—

Current ratio2.1×+0.3×

Segments

By product

See full

Gross product sales$66.2M+58.3%

Delivery of drug supplies, royalties and others$7.1M+15.0%

Development Milestones-—

Release Of Share Cost Liability-—

Discounts and allowances-$19.7M-60.2%

Versus estimates

Revenue

Q1 2026$58.8MMiss by $3.6M Q4 2025$69.8MBeat by $1.1M Q3 2025$69.5MBeat by $1.0M Q2 2025$101.7MBeat by $39.4M Q1 2025$53.3MBeat by $5.0M

Q4 2024$57.6MIn line

Diluted EPS

Q1 2026$0.44Miss by $0.30 Q4 2025$1.14Miss by $0.19 Q3 2025$1.46Beat by $0.53 Q2 2025$3.28Beat by $1.31 Q1 2025$0.63Beat by $0.49

Q4 2024$0.80Beat by $0.50

Ask the moment Rigel Pharmaceuticals reports.

Connect your AI and ask the moment the filing drops. It reads the release, surfaces what management said, and gives you its own read.

Connect your AI

Claude

Questions, answered.

When did Rigel Pharmaceuticals report Q4 2024 earnings?: Rigel Pharmaceuticals (RIGL) reported Q4 2024 earnings on March 4, 2025 after market close.
What were Rigel Pharmaceuticals's Q4 2024 revenue and EPS?: Rigel Pharmaceuticals reported revenue of $57.6M and eps of $0.80 for Q4 2024.
Did Rigel Pharmaceuticals beat estimates in Q4 2024?: Revenue beat the consensus estimate of $57.6M by $6.0K. EPS beat the consensus estimate of $0.30 by $0.50.
Where can I find Rigel Pharmaceuticals's Q4 2024 SEC filings?: You can read the 10-K periodic report (0001558370-25-002169) directly on SEC EDGAR. The filing index links above go to sec.gov.